000 04615nam a22003735i 4500
001 280771
003 MX-SnUAN
005 20160429154037.0
007 cr nn 008mamaa
008 150903s2009 xxu| o |||| 0|eng d
020 _a9780387895208
_99780387895208
024 7 _a10.1007/9780387895208
_2doi
035 _avtls000333309
039 9 _a201509030227
_bVLOAD
_c201404130414
_dVLOAD
_c201404092203
_dVLOAD
_y201402041108
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aR-RZ
100 1 _aGrewal, Iqbal S.
_eeditor.
_9305944
245 1 0 _aTherapeutic Targets of the TNF Superfamily /
_cedited by Iqbal S. Grewal.
264 1 _aNew York, NY :
_bSpringer New York,
_c2009.
300 _axvii, 220 páginas
_brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
490 0 _aAdvances in Experimental Medicine and Biology,
_x0065-2598 ;
_v647
500 _aSpringer eBooks
505 0 _aOverview of TNF Superfamily: A Chest Full of Potential Therapeutic Targets -- Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges -- Targeting TNF for Treatment of Cancer and Autoimmunity -- Targeting of BAFF and APRIL for Autoimmunity and Oncology -- The Role of FasL and Fas in Health and Disease -- OX40 (CD134) and OX40L -- Targeting CD70 for Human Therapeutic Use -- 4-1BB as a Therapeutic Target for Human Disease -- RANK(L) as a Key Target for Controlling Bone Loss -- Targeting the LIGHT-HVEM Pathway -- GITR: A Modulator of Immune Response and Inflammation -- Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases -- Tumor Necrosis Factor Receptor Superfamily Member 21: TNFR-Related Death Receptor-6, DR6 -- TRAIL and Other TRAIL Receptor Agonists as Novel Cancer Therapeutics -- Therapeutic Potential of VEGI/TL1A in Autoimmunity and Cancer.
520 _aTumor necrosis factor (TNF) superfamily is a rapidly growing family of cytokines that interacts with a corresponding superfamily of receptors. Ligand-receptor interactions of this superfamily are involved in numerous biological processes ranging from hematopoiesis to pleiotropic cellular responses, including activation, proliferation, differentiation, and apoptosis. The particular response depends on the receptor the cell type, and the concurrent signals received by the cell. Worldwide interest in the TNF field surged dramatically early in 1984 with the cloning and defining of the profound cellular effects of the first member of this family, TNFa. Subsequently, the major influence of TNFa on the development and functioning of the immune system was established. Today, over 20 human TNF ligands and their more than 30 corresponding receptors have been identified. Few receptors still remain orphans. What has emerged over the years is that most TNF ligands bind to one distinct receptor and some of the TNF ligands are able to bind to multiple TNF receptors, explaining to some extent the apparent disparity in the number of TNF receptors and ligands. Yet, in spite of some redundancy in TNF ligand/receptor interactions, it is clear that in vivo spatial, temporal, and indeed cell- and tissue-specific expression of both ligands and their receptors are important factors in determining the precise nature of cellular physiological and pathological processes they control. Therapeutic Targets of the TNF Superfamily presents the state-of-the art account on the role of TNF superfamily members in the pathogenesis and their use in current intervention of cancers and autoimmune disease. This text will be highly valuable for investigators to understand the disease processes regulated by TNF superfamily members and to develop effective therapeutics. A view into the future, inspired by the comprehensive work presented in this volume, predicts that researchers studying TNF superfamily members will continue to make rapid progress in identifying relevant components to the disease process and new therapeutic strategies to target many human diseases including cancers, autoimmune disease and others.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9780387895192
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-0-387-89520-8
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c280771
_d280771